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Design: Multicenter, single-arm, objective performance criteria (OPC)-controlled international study (Canadian Task Force
classification II-1).
Setting: Seven academic medical centers.
Patients: 105 premenopausal women symptomatic for menorrhagia secondary to dysfunctional uterine bleeding.
Intervention: Patients were treated using the Minerva endometrial ablation system.
Measurements andMain Results: Study success, based on a pictorial blood loss assessment chart (PBLAC) score%75, was
observed in 96.2% of the patients at 1 year posttreatment. Some 69.5% of the patients experienced amenorrhea (PBLAC score
0). The mean duration of the procedure was 3.9 minutes. General anesthesia was used in 9% of cases, with the balance being
performed under local and/or intravenous or spinal anesthesia regimens. No intraoperative adverse events and/or complica-
tions were reported. No patient required hysterectomy or any additional medical and/or surgical interventions to control
bleeding during 1 year of follow-up. Efficacy (success) results were compared between the Minerva system and the OPC,
which served as a statistical control. The OPC comprised the US Food and Drug Administration’s (FDA) reported success
rates of all FDA-approved endometrial ablation systems. TheMinerva system had a statistically significantly superior success
rate compared with the OPC control.
Conclusion: The Minerva system was found to be safe and effective for treating patients suffering from menorrhagia. The pro-
cedure is quick and effective, does not require endometrial pretreatment, and precludes the need for additional surgical interven-
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DeCherney et al [2], Vancaillie [3], and others, endometrial
ablation is now used worldwide as a safe and less invasive
alternative to hysterectomy for the management of
menorrhagia. Despite its early promise, however, the initial
adoption of this technique was slowed by the general lack of
2 Journal of Minimally Invasive Gynecology, Vol-, No-,-/- 2015advanced hysteroscopic and resectoscopic skills, coupled
with concerns about the use of nonelectrolyte solutions for
uterine distention [4,5]. Fueled by the unmet need, a
generation of nonhysteroscopic devices was introduced to
ablate the endometrium using safer and less skill-intensive
methods. Following US Food and Drug Administration
(FDA) approval of the first such device, the ThermaChoice
UBT in 1997, others, including Her Option (cryosurgery),
HydrothermAblator (hot saline), NovaSure (bipolar
radiofrequency [RF]), and MEA (microwave energy), were
sequentially approved. Using a prospective randomized
controlled trial (RCT) design for each pivotal trial, the
effectiveness and safety of each method was shown to be
noninferior to that of rollerball endometrial ablation [6–15].
Despite the fact that endometrial ablation has been estab-
lished as a safe and conservative alternative to hysterectomy
and its use continues to expand [16], the impact of this less
invasive procedure on the overall rate of hysterectomy has
not been significant to date. Recent US data indicate that
the hysterectomy rate has remained relatively constant at
600 000 cases/year [17]. There are also concerns about the
interval surgical interventions, such as reablation and/or
hysterectomy, performed for recurrent menorrhagia and/or
new pelvic pain [18–20].
The Minerva endometrial ablation system (Minerva
Surgical, Redwood City, CA) was developed with the goal
of exceeding established outcomes by using a novel
technology. The Minerva system has been evaluated in a
number of extirpated and perihysterectomy studies aimed
at assessing the system’s safety and efficacy. As such, the
primary objective of the present study was to evaluate the
safety and effectiveness of the Minerva endometrial ablation
system, as evidenced by a reduction of bleeding to a normal
menstrual blood loss level (defined as a score of%75 on a
pictorial blood loss assessment chart [PBLAC]) at 12months
posttreatment and the absence of any adverse events.
Secondary objectives included amenorrhea rate, treatment
parameters (procedure time, anesthesia type), patient
satisfaction, and responses to a validated quality of life
(QoL) questionnaire.Materials and Methods
General
As part of the premarket approval submission to the FDA,
the results of this study were used to assess the safety and ef-
ficacy of the Minerva endometrial ablation system. This
investigation was a prospective, single-arm, multicenter,
objective performance criteria (OPC)-controlled interna-
tional study. The study was conducted at 7 academic centers
in Canada, Mexico, and Hungary in accordance with the In-
ternational Conference on Harmonisation’s good clinical
practices (GCP), including recommendations guiding physi-
cians in biomedical research involving human subjects
adopted by the 18th World Medical Assembly (1964 andlater revisions) and standard ISO14155. In addition, the
study design and execution complied with regulatory re-
quirements developed and adopted by the FDA. The study
protocol, informed consent document, case report forms,
and other relevant documentation were all reviewed and
approved by pertinent institutional review boards and
country-specific regulatory bodies. Adherence to the GCP
guidelines was monitored by ICRC, Inc (Encinitas, CA),
an independent clinical research organization. To ensure sta-
tistical integrity and to avoid site-to-site cross-
contamination, the data collection and management were
conducted by a separate, independent clinical research orga-
nization (Medpace, Inc, Cincinnati, OH). Data entry and
overall management were performed using Clindex clinical
trial software (Fortress Medical Systems, Hopkins, MN).
Study progress was also critically monitored by 2 inde-
pendent entities composed of experts in the field of gynecol-
ogy and endometrial ablation. A Data Safety Monitoring
Board (DSMB) was tasked to oversee the overall progress
and safety of the study. A Clinical Events Committee
(CEC) assessed and ultimately adjudicated all observed
adverse events with respect to severity and relationship to
the device and/or the procedure. Both the DSMB and the
CEC had the authority to recommend study termination in
the event that patient safety was compromised and/or the ef-
ficacy data did not support or justify future recruitment of
subjects.Clinical Protocol
The primary objective of the present study was to eval-
uate the safety and effectiveness of the Minerva endometrial
ablation system, as evidenced by reduction in bleeding to a
normal menstrual blood loss level (defined as a PBLAC
score %75) at 12 months posttreatment and the absence of
adverse events. Secondary objectives included amenorrhea
rate, treatment parameters (procedure time, anesthesia
type), patient satisfaction, and responses to validated QoL
and menstrual impact questionnaires.Blood Loss Assessment
Menstrual bleeding volume was assessed using the
PBLAC scoring system described by Higham et al [21]. Us-
ing the Higham methodology, a PBLAC score of 100 has
been shown to have a sensitivity of 86% and a specificity
of 89% for the diagnosis of menorrhagia (.80mLmenstrual
blood loss per cycle). Before study initiation, a separate san-
itary product validation study was conducted to ensure accu-
rate correlation between the absorption of each sanitary
product and the Higham scoring method. Study subjects
were instructed to use only validated sanitary products,
which were provided free of charge. Bleeding levels were as-
sessed preoperatively, and all candidates had to satisfy a
minimum PBLAC score of 150 per cycle to qualify for study
participation.
Fig. 1
OPC success calculation.
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monthly from month 2 through month 12. Patients reporting
amenorrhea were instructed to document the total absence of
bleeding on each monthly diary.Inclusion/Exclusion Criteria
Subjects eligible for study participation were required to
be premenopausal (follicle-stimulating hormone level ,40
mIU/mL), between 25 and 50 years of age, have no desire
for fertility, and a documented PBLAC score confirming
menorrhagia without a definable cause. Uterine sounding
length was limited to 10 cm and cavity width to no smaller
than 2.5 cm. Subjects were not permitted to use any form
of hormonal birth control during the follow-up period, to
eliminate the possibility that posttreatment bleeding reduc-
tion was induced by and/or attributed to the suppressive ac-
tion of hormonal contraceptives. Subjects were required to
demonstrate literacy and the ability to accurately use men-
strual diaries.
Subjects were excluded if they presented with evidence of
pelvic inflammatory disease, active/acute endometritis,
sexually transmitted disease, bacteremia, sepsis, other active
local and/or systemic infection, untreated/unevaluated cervi-
cal dysplasia (except CIN I), endometrial hyperplasia, or
known or suspected abdominal or pelvic cancer. Subjects
with suspected or known coagulopathies, receiving anticoa-
gulation therapy, or diagnosed with a congenital malforma-
tion of the uterus, fibroid(s) distorting the uterine cavity, or
large endometrial polyp(s), and those less than 6 weeks post-
partum were excluded from study participation.Fig. 2
The Minerva endometrial ablation system.Statistics and the OPC Control
This investigation was designed as a single-arm study
comparing the effectiveness of the Minerva endometrial
ablation system with that of the OPC control recommended
by the FDA. The analysis of success rates for the 5 previously
approved endometrial ablation devices was performed and
provided by the FDA. Based on these data (Her Option,
67.4%; HydroThermablator, 68.4%; Microwave Endome-
trial Ablation/MEA, 87%; NovaSure, 77.7%; Therma-
Choice, 75.4%), the calculated least squares mean success
rate for the OPC was 75.6%, with lower and upper 95% con-
fidence bounds of 65.6% and 83.5%, respectively (Fig. 1).
The study sample size to obtain at least 80% power, thereby
detecting a difference between the expectedMinerva success
rate of approximately 78% and the lower confidence bound
of the OPC of 66%, required a minimum of 91 subjects.
Assuming a dropout rate of 10% at 12 months, the required
enrolled sample size was determined to be 102 subjects.
The Minerva system was studied at 7 clinical sites. Pool-
ing of the data was justified by implementation of virtually
identical protocols across all clinical sites and the methodol-
ogy described by Meinert [22]. A Fisher-Freeman-Halton
test of the rates of success was used to test whether the inves-tigational sites differed in the primary endpoints with respect
to primary effectiveness. The test for homogeneity of
response was based on a 2-sided test at a 0.10 level of signif-
icance. Demographic and baseline characteristics were sum-
marized descriptively by mean, standard deviation (SD),
number evaluated, median, minimum and maximum for
continuous variables and number evaluated, percentage,
and 95% exact confidence limit on the percentage for cate-
gorical variables. Additional statistical methods were docu-
mented, and statistical soundness was ensured by the
development of a formal statistical plan before study initia-
tion. This plan outlined strict definitions and rules regarding
data analysis related to subject accountability, missing data
procedures, and safety, as well as effectiveness.
Statistical analysis was conducted by an independent
contractor (Willes Consulting Group, Encinitas, CA) using
SAS version 9.2 (SAS Institute, Cary, NC).Minerva Endometrial Ablation System: Principles of
Operation
The Minerva endometrial ablation system (Fig. 2) is de-
signed to treat abnormal uterine bleeding due to benign
Fig. 3
The sealed silicone membrane covering the plasma formation array of
the Minerva endometrial ablation system.
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complete. It consists of the Minerva surgical RF controller
and the disposable endometrial ablation handpiece.
The Minerva endometrial ablation system uses bipolar
RF electrical current at a frequency of 480 kHz to ionize
argon (Ar) gas, which is fully contained and circulating
within a sealed silicone membrane covering the plasma for-
mation array (PFA) (Fig. 3). This PFA is inserted and de-
ployed in the uterine cavity. When the system is energized,
the low-pressure (w25 mmHg) Ar gas that is circulatingwithin the array membrane is ionized, transforming it into
plasma. Moving at the speed of light, these ionized particles
transform their kinetic energy into thermal energy on
colliding with the silicone membrane. In this fashion, the
Ar plasma heats the silicone membrane, and thermal energy
is conducted into the adjacent endometrium.
During the ablation cycle, the Minerva system does not
proactively evacuate the liquid contents from the uterine
cavity. These liquids remain in the uterine cavity, are heated
by the membrane, and are used to ablate the endometrial tis-
sue that is not in direct contact with the membrane. This is
especially helpful when the cavity is distorted by small intra-
cavitary or intramural pathology or when the uterine cavity
lacks axial symmetry. This ‘‘triple’’ mechanism of action
combines direct membrane-to-tissue heat transfer with the
ablative effect of the retained heated liquids, along with
the tissue penetrating bipolar RF current in an impedance-
mediated resistive heating environment, creating a uniform
and reproducible ablation of the endometrium.Minerva RF Controller
The Minerva surgical RF controller is a RF power unit
that generates, monitors, and manages energy delivery to
the device. The power delivered to the disposable handpiece
by the Minerva surgical RF controller varies according to
electrophysical changes in the impedance characteristics of
the endometrial tissue during the ablation process. As the
ablation progresses and tissue impedance rises, the initial
power level of approximately 40 W gradually drops corre-
spondingly, reaching subtherapeutic levels at the end of
the procedure. Whereas the total amount of energy delivered
(power [W]! time [seconds]) will vary from patient to pa-
tient, the total ablation time is a constant 2 minutes. In addi-
tion, the RF controller performs a uterine integrity test (UIT)
designed to identify possible defects of the uterine wall and/
or the array membrane by introducing and monitoring the
change (decay) in the flow rate of CO2 gas. The RF
controller graphic user interface guides the user through
each step of the procedure.Minerva Disposable Device
The wet silicone membrane ensures a very low friction
environment, facilitating easy insertion and deployment.
The UIT is a preventive safety feature to help assess the uter-
ine cavity for possible uterine and/or array membrane de-
fects. During the UIT, CO2 gas is instilled into the space
between the PFA membrane and the endometrial surface.
Simultaneously, vacuum/suction is drawn on the inside of
the PFA, allowing CO2 to freely fill the space outside the
membrane. In this fashion, both the integrity of the uterine
wall and the membrane are assessed by measuring CO2
flow decay. If the CO2 flow rate remains high, the UIT will
produce an alarm and halt the procedure. If the flow rate
Table 2
Intraoperative data
Variable Value
Uterine position (n 5 105), n (%)
Anteverted 81 (77.1)
Retroverted 17 (16.2)
Mid-position 7 (6.7)
Laberge et al. Safety and Efficacy of the Minerva Endometrial Ablation System 5drops and remains below a prespecified level, the systemwill
automatically initiate the ablation cycle.
The distal tip of the sheath is equipped with a cervical seal-
ing balloon that, when inflated, seals the cervical canal and
the uterine cavity. On successful completion of the UIT, the
ablation cycle starts automatically, and plasma energy is
then delivered. With completion of the 2-minute ablation cy-
cle, the cervical balloon is deflated, the array is closed, and the
device is removed from the uterine cavity.Sounding length, cm (n 5 105)
Mean 6 SD (median) 8.6 6 0.9 (8.5)
Range (min, max) (7.0, 10.0)
Cavity length, cm (n 5 105)
Mean 6 SD (median) 5.1 6 0.7 (5.0)
Range (min, max) (4.0, 7.0)
Cervical dilation, mm (n 5 105)
Mean 6 SD (median) 7.2 6 0.3 (7.0)
Range (min, max) (6.5, 8.5)
Procedure time, min (n 5 104)
Mean 6 SD (median) 3.9 6 1.5 (3.0)
Range (min, max) (1, 11)
SD 5 standard deviation.Results
Efficacy Results
A total of 110 premenopausal subjects with menorrhagia
were included at 7 clinical sites. Informed consent was pro-
vided by each subject. Five subjects did not meet the inclu-
sion criteria and were excluded during preoperative
screening. The Minerva procedure was subsequently
attempted in 105 subjects and was successful in all but 1
patient, who had a uterine cavity width of ,2.5 cm
(exclusion criterion) at the time of the operative visit and
underwent rollerball ablation outside of the study protocol.Table 1
Demographic data (ITT population, n 5 105)
Characteristic Value
Age, yr
Mean 6 SD (median) 41.9 6 5.3 (43.2)
Range (min, max) (29.3, 49.7)
Race/ethnicity, n (%)
Hispanic 26 (24.8)
Asian 1 (1)
Caucasian 78 (74.3)
Body mass index, kg/m2
Mean 6 SD (median) 27.8 6 5.0 (27.3)
Range (min, max) (18.0, 43.3)
Gravida
Mean 6 SD (median) 2.9 6 1.4 (3.0)
Range (min, max) (0, 6)
Para
Mean 6 SD (median) 2.3 6 1.0 (2.0)
Range (min, max) (0, 5)
Menstrual history, n (%)
Regular cycle pattern 90 (85.7)
Dysmenorrhea 62 (59.1)
PMS 77 (73.3)
PBLAC score at baseline
Mean 6 SD (median) 472.6 6 342.1 (382.8)
Range (min, max) (151.1, 2048.0)
FSH, IU/L
Mean 6 SD (median) 7.9 6 7.2 (6.0)
Range (min, max) (0.4, 38.0)
FSH5 follicle-stimulating hormone; PBLAC5 pictorial blood loss assessment
chart; PMS 5 premenstrual symptoms; SD 5 standard deviation.This subject was included in the intention-to-treat (ITT)
group for calculating success and amenorrhea rates.
A total of 104 patients underwent the Minerva procedure,
and all completed their 12-month follow-up visits. The ho-
mogeneity of the primary endpoint across investigational
sites and countries was tested using the Fisher-Freeman-
Halton extension of Fisher’s exact test. The assumption of
homogeneity across both sites and countries was not rejected
(p 5 .14 and 1.00, respectively). Because the hypothesis of
homogeneity of response across sites and countries had been
justified, and each investigational site conducted the study
under a common protocol, we concluded that the primary
endpoints may be pooled across study sites and countries
for the effectiveness analyses.
Data on patient baseline demographics, gynecologic his-
tory, and other intraprocedural data are presented in Tables 1
and 2. The anesthesia regimens were ultimately left up to the
discretion of each patient, investigator, and/or
anesthesiologist while considering guidelines and anesthesia
protocols adopted by each site. General anesthesia was used
in 8.6% of the patients, paracervical block in 9.6%, and
intravenous sedation in 11.4%. The balance received a
combination of intravenous sedation, paracervical block, and
other (unspecified) anesthesia regimens. The mean
procedure time (interval from device insertion to device
removal) was 3.96 1.5 minutes (median, 3.0 minutes).
Treatment success was based on a reduction in diary score
from PBLAC .150 pretreatment to PBLAC %75 at the
1-year follow-up. The effectiveness (success) rate based on
the ITT population at 1 year of follow-up was 96.2%. The
statistical hypothesis of this clinical study was supported,
as detailed below.
Fig. 4
Success rates of OPC and Minerva.
Fig. 5
Temporal trending of clinical outcomes.
Table 3
Adverse events
Adverse event n (%)
Anesthesia-related 23 (21.9)
Infection, vaginal 1 (1)
Bleeding 7 (6.7)
Endometritis 1 (1)
Pelvic cramping (nonspecific) 71 (67.6)
Pelvic cramping (dyspareunia) 1 (1)
Abdominal pain 3 (2.9)
Nausea more than 24 h posttreatment 2 (1.9)
Vaginal discharge 14 (13.3)
Urinary tract infection 5 (4.8)
Pelvic inflammatory disease 1 (1)
Fever (.37C) more than 24 h posttreatment 2 (1.9)
Other 33 (31.4)
Total 105 (100)
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determine whether the Minerva success rate of 96.2% was
statistically significantly equal to or lower than the OPC con-
trol’s 95% lower confidence bound of 66%. In a binomial
test of the null hypothesis, based on the success rate of
96.2% observed in the Minerva ITT population, the null hy-
pothesis was rejected, and the 12-month follow-up success
rate observed with the Minerva endometrial ablation system
was demonstrated to be statistically significantly superior to
the OPC’s lower confidence bound of 66% (p , .0001). A
secondary analysis performed using the same approach
demonstrated that the 96.2% success rate of the Minerva
procedure was statistically significantly superior to the
OPC’s 95% upper confidence bound of 83.5% (p , .0001)
(Fig. 4).
The Minerva success rate was stratified and analyzed as a
function of age at the time of theMinerva procedure. Patients
were divided into 2 groups: age %40 years and age .41
years. The treatment success rate of 97.4% (37 of 38) in
25- to 40-year-olds was not statistically different from the
95.5% (64 of 67) reported in the 41- to 50-year-olds (p 5
1.00, 2-sided Fisher’s exact test).
Endometrial pretreatment (medical/surgical) was not
used in this study, and the procedure was not timed to any
particular menstrual cycle day. The procedure was per-
formed even if the patient was actively bleeding at the
time of the operative visit. As such, we conducted a separate
stratification and comparison of effectiveness of theMinerva
endometrial ablation system as a function of menstrual cycle
phase at the time of the procedure. Only patients reporting a
regular menstrual cycle (n5 90) were included in this anal-
ysis. Patients who underwent the Minerva procedure during
the proliferative phase (n 5 45) reported success rates
similar to those who did so during the secretory phase (n
5 45) (97.8% and 95.6%, respectively; p 5 1.00, Fisher’s
exact test). In addition, success rates were not statistically
different between subjects with irregular cycles (n 5 15)
and those with regular cycles (n 5 90) (93.3% vs 96.7%; p
5 .47, Fisher’s exact test).The secondary effectiveness objective was the rate of
amenorrhea, defined as a PBLAC of 0, at the at 12-month
follow-up. Calculated for the ITT population of 105 sub-
jects, this rate was 69.5%.
During the 12-month follow-up period, no subjects
required a hysterectomy or any additional medical and/or
surgical interventions to control uterine bleeding. No
patients were lost to follow-up during the study.
Bleeding diaries were collected monthly starting at
month 2 and continuing through month 12. To assess
bleeding pattern trends, PBLAC scores were categorized
as amenorrhea, PBLAC 0; spotting: PBLAC 0.1 to 10; hypo-
menorrhea, PBLAC 10.1 to 30; eumenorrhea, PBLAC 30.1
to 75; or menorrhagia, PBLAC .75. Figure 5 shows
bleeding trends over the course of the study. Listing absolute
PBLAC scores by category demonstrates a trend toward an
increasing rate of amenorrhea along with a decreasing rate
of spotting. In other words, those with spotting tend to
become amenorrheic, whereas those with hypomenorrhea,
Laberge et al. Safety and Efficacy of the Minerva Endometrial Ablation System 7eumenorrhea, or menorrhagia are not likely to experience a
significant change in bleeding pattern.
At study entry, subjects were asked whether they experi-
enced premenstrual symptoms (PMS) and/or dysmenorrhea.
For those with symptoms, 80.8% and 54.8% experienced a
reduction in PMS and dysmenorrhea, respectively, at 12
months.
Safety Results
Safety of the Minerva endometrial ablation system was
evaluated by recording all adverse events. Investigators
conservatively recorded all signs and symptoms typically
experienced following an endometrial ablation procedure
(i.e., vaginal discharge, pelvic pain, abdominal cramping,
vaginal bleeding, nausea, and vomiting) as adverse events
(Table 3).
No serious or unanticipated device-related adverse events
were recorded during the course of the study. The sole
serious adverse event was not related to the study device
or procedure. That patient required a preplanned artificial
heart valve implant at approximately 8.5 months posttreat-
ment. In addition, a 43-year-old patient conceived at 11
months after theMinerva procedure and subsequently under-
went an uneventful dilation and curretage for a missed abor-
tion. This event was adjudicated by the CEC/DMC as
unrelated to the study device.
QoL Results
A menstrual impact questionnaire was administered at
baseline and again at the 3-month, 6-month, and 12-month
follow-up visits. Scores were assigned to each response,
and a paired t-test was applied to each question listed to eval-
uate the change between baseline and the 12-month visit. ForTable 4
Responses to the QoL questionnaire
Patients responding ‘‘sometimes,’’ ‘‘frequently,’’ or ‘‘always’’ to
Feel like yourself?
Lack of desire or interest in sexual activities (if sexually active)?
Feel you accomplished less than desired due to menses?
Lack confidence in yourself due to menses?
Have decreased pleasure or arousal during sexual activity (if sexually active)?
Have difficulty performing work or other activities due to menses?
Have difficulty concentrating?
Have less energy or a total lack of energy due to menses?
Feel you lacked control over your life?
Spend less time at work or other activities outside your home due to menses?
Feel tired or worn out?
Have sexual relations less frequently than you desired due to menses (if sexua
Feel physically attractive?
Feel anxious due to menses?
Feel irritable?
Miss athletic activities due to menses?
Unable to work outside the home due to menses?all questions, there was a statistically significant difference
in the subjects’ responses at 12 months compared with base-
line (Table 4).
At the 12-month assessment of patient satisfaction with
the Minerva procedure, 97.6% reported being ‘‘satisfied’’
or ‘‘very satisfied.’’ Moreover, 98.8% stated that they would
recommend the procedure to a friend or a relative, with only
1.2% reporting ‘‘not sure.’’Discussion
Our methodology used a wide range of complementary
study controls, including regulatory compliance; use of a
CEC, a DSMB, and a statistical plan; and validation of the
sanitary products for calculation of PBLAC score. Although
complex and logistically challenging, this approach assured
soundness of the study, generated the highest-quality data,
and minimized bias during data interpretation. Compared
with dropout rates as high as 25% in similar clinical trials,
patient follow-up and compliance during this study were
exemplary, with 100% completion of the 12-month visit.
Such compliance may be attributable, among other factors,
to the geographic location of the clinical sites, where subject
population is in general less prone to migration.
The OPC approach for comparing the primary endpoint
of a study (success) is widely used in both pharmacologic
and medical device research. The present Minerva study
is the first investigational study of endometrial ablation to
use the OPC model in preparation for FDA approval of
the device. The primary strength of this OPC study is its
ability to compare the success rates of the Minerva system
and the OPC composed of all 5 FDA-approved endometrial
ablation systems, using data from their respective FDA
pivotal RCTs. On the other hand, a potential weakness ofBaseline, % 12-mo follow-up, % p value
78.5 96.3 ,.0001
65.4 30.1 ,.0001
78.16 9.63 ,.0001
59.77 8.43 ,.0001
51.2 13.2 ,.0001
78.17 9.63 ,.0001
73.8 16.9 ,.0001
96.55 21.69 ,.0001
59.5 9.6 ,.0001
77.01 7.22 ,.0001
95.3 33.7 ,.0001
lly active)? 66.71 13.2 ,.0001
58.3 80.8 ,.0001
74.72 12.04 ,.0001
88.1 46.9 ,.0001
77.02 6.02 ,.0001
57.46 7.22 ,.0001
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ization, known to effectively address such important study
elements like ‘‘washout’’ of population bias and blinding/
masking, which are better addressed using a RCT study
model. This deficiency is currently being addressed
through an ongoing RCT with rollerball ablation serving
as the control.
TheMinerva success rate of 96.2% compares favorably to
the success rate of the OPC control. The statistically signif-
icant (p, .0001) superiority of the Minerva system over the
OPC’s 95% upper confidence bound of 83.5% indicates that
theMinerva system design is a potential improvement on the
technical limits of comparative systems.
The reported amenorrhea rate of 69.5% for the Minerva
system may be attributable to the system’s use of the triple
mechanism of action approach in endometrial tissue abla-
tion. Simultaneous use of bipolar RF ablation, direct thermal
energy transfer frommembrane to tissue, and thermal energy
transfer from the heated fluids present in the uterine cavity
for the purpose of filling the potential gaps between the array
and endometrium appears to provide a very interesting pro-
cedural solution. Theoretically, then, this device design al-
lows for a more adequate ablation independent of uterine
cavity geometry or adequacy of device deployment. Previous
research has demonstrated that achieving amenorrhea is
highly desirable and results in very high patient satisfaction
rates [23], whereas failure to achieve amenorrhea commonly
leads to hysterectomy [24]. Given that all patients were able
to avoid hysterectomy at the 12-month follow-up, the 69.5%
rate of amenorrhea coupled with the 96.2% success rate may
serve to reduce the need for extirpative therapy in this popu-
lation. These promising results require corroboration using
longer follow-up to more fully evaluate, understand, and ul-
timately validate the role of the Minerva procedure.
Comparatively, the procedure time with the Minerva
system was very short. On average, the total time from de-
vice insertion to device removal was 3.9 minutes. The
degree of cervical dilation was similar to or less than
that seen with the other devices. The short procedure
time, small diameter, ease of device deployment, and
low power level may allow for use of the Minerva system
in the office setting. Intraoperative discomfort was not
measured in this study and may be an area of interest
for future research.
During the last decade, the impact of surgical treatment
on overall QoL has been a key validator for clinical value.
Research trends observed in Europe, Australia, and other
countries indicate that QoL is even more important than
other predefined and absolute values for study success
(e.g., bleeding). In this study, on a validated QoL question-
naire administered 12 months after the procedure, subjects
reported a statistically significant improvement in every
category, including 97.6% who were satisfied with the
outcome and 98.8% who would recommend the procedure
to a friend. Along with reducing menstrual bleeding, the
Minerva procedure reduced PMS by 80.8% and dysmenor-rhea by 54.8%. The exact mechanism of PMS reduction after
endometrial ablation is not understood and has been reported
in other endometrial ablation research. Investigators theorize
that this effect may result from reduced anxiety in anticipa-
tion of an excessive period after the condition has been suc-
cessfully treated. Decreased dysmenorrhea, another known
outcome of endometrial ablation, may be attributed to the
possible effect of ablation on superficial adenomyosis,
with endometrial glands located within the zone of ablation
front effectively destroyed. It is critical to understand and
appreciate that this type of outcome should not be promised
to the patient during counseling, considering that endome-
trial ablation (of any kind) is not a solution in the manage-
ment of adenomyosis.
The Minerva device was highly rated by the investigators
with respect to ease of use and overall user satisfaction. The
device was easy to insert and deploy, and required minimal
to no seating. Use of the cervical sealing balloon for cervical
canal occlusion during the UIT resulted in 100% adequate
occlusion on the first attempt. The overall performance of
the device was rated ‘‘excellent’’ or ‘‘good’’ in 98.1% (102
of 104) of the treated cases. In all attempted cases, the inves-
tigators responded that they ‘‘would recommend use of the
device.’’
Conclusion
This multicenter study demonstrates that at 12-month
follow-up, the Minerva endometrial ablation system and
procedure are safe and effective while producing results
that were statistically significant superior compared with
the OPC control. Moreover, theMinerva procedure produces
high amenorrhea and patient satisfaction rates, is fast, easy
to use, does not require general anesthesia and should be
considered a minimally invasive treatment method of choice
such that hysterectomy is ultimately avoided.
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